10-Q: Cara Therapeutics Reports Q1 2024 Results, Focuses on Oral Difelikefalin Development

Cara Therapeutics reported its first quarter 2024 financial results, highlighting a strategic shift towards the development of oral difelikefalin for notalgia paresthetica (NP) and a workforce reduction.

Summary

• Cara Therapeutics reported a net loss of $30.7 million for the first quarter of 2024, compared to a net loss of $26.7 million for the same period in 2023.
• The company's total revenue decreased to $2.1 million in Q1 2024 from $6.2 million in Q1 2023, primarily due to reduced collaborative and commercial supply revenue.
• Operating expenses were $31.8 million in Q1 2024, which included $2.4 million in restructuring costs related to a workforce reduction.
• Research and development expenses decreased to $22.0 million in Q1 2024 from $24.3 million in Q1 2023.
• The company is focusing on the development of oral difelikefalin for chronic pruritus associated with notalgia paresthetica (NP), with topline results from the dose-finding portion of the Phase 2/3 program expected by the end of the second quarter of 2024.
• Cara Therapeutics sold its future ex-U.S. royalties and milestones for Kapruvia and KORSUVA to HCR for up to $40 million, resulting in a non-cash interest expense of $2.0 million in Q1 2024.
• The company's cash and cash equivalents and marketable securities totaled $69.8 million as of March 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company is making strategic shifts and focusing on a new indication, the financial results are concerning, with decreased revenue and increased losses. The sale of future royalties and milestones also raises concerns about long-term revenue potential. The company's stock price is also a concern.

Positives

• The company is focusing on a promising new indication for oral difelikefalin in notalgia paresthetica (NP).
• Enrollment is complete for the dose-finding portion of the Phase 2/3 KOURAGE 1 study.
• The company has taken steps to reduce operating expenses through a workforce reduction.
• The company has secured funding through the sale of future royalties and milestones.

Negatives

• The company experienced a significant decrease in revenue compared to the same period last year.
• The company reported a net loss of $30.7 million for the quarter.
• The company expects no meaningful revenue contribution from KORSUVA injection following the TDAPA period expiration.
• The company's commercialization of KORSUVA injection has not met expectations.

Risks

• The company is subject to risks common to other life science companies, including uncertainty of product development and commercialization.
• The company has incurred substantial net losses and negative cash flows from operating activities and expects this trend to continue.
• The company's ability to raise additional financing is uncertain.
• The company's future revenue is dependent on the success of its clinical trials and commercialization efforts.
• The company's stock price is below $1.00, and it has until July 30, 2024, to regain compliance with Nasdaq's bid price requirement.

Future Outlook

The company expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund its currently anticipated operating plan into 2026. The company expects no meaningful revenue contribution from KORSUVA injection following the TDAPA period expiration and no meaningful revenue contribution from KORSUVA/Kapruvia royalties and milestones in the foreseeable future.

Management Comments

• The company is focusing its efforts on the development of oral difelikefalin in chronic pruritus associated with notalgia paresthetica.
• The company has implemented a workforce reduction to reduce operating expenses.
• The company expects topline results from the dose-finding portion of the Phase 2/3 program for oral difelikefalin in NP by the end of the second quarter of 2024.

Industry Context

The company's strategic shift towards oral difelikefalin for NP reflects a growing focus on addressing unmet needs in chronic pruritus. The company's decision to sell its future ex-U.S. royalties and milestones for Kapruvia and KORSUVA to HCR is a strategic move to secure funding for its pipeline development.

Comparison to Industry Standards

• The decrease in revenue from KORSUVA injection is concerning, as it indicates challenges in the commercialization of the product, which is a common issue for pharmaceutical companies launching new drugs.
• The company's focus on oral difelikefalin for NP is a strategic move to diversify its pipeline and address a new market, which is a common strategy for biotech companies.
• The workforce reduction is a common cost-cutting measure for biotech companies facing financial challenges, but it may impact the company's ability to execute its development plans.
• The sale of future royalties and milestones is a common financing strategy for biotech companies, but it may limit the company's future revenue potential.
• The company's cash runway into 2026 is relatively short compared to other biotech companies, which typically aim for a longer runway to fund their development programs.

Related Party Transactions

• CSL Vifor and its affiliates are considered related parties.
• Vifor International owned 7,396,770, or 13.5%, of the company's common stock as of March 31, 2024.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and the decrease in revenue.
• Employees have been impacted by the workforce reduction.
• Customers may be impacted by the company's strategic shift and focus on oral difelikefalin for NP.
• Suppliers may be impacted by the company's reduced manufacturing commitments.

Next Steps

• The company expects topline results from the dose-finding portion of the Phase 2/3 KOURAGE 1 study for oral difelikefalin in NP by the end of the second quarter of 2024.
• The company plans to initiate the pivotal Phase 3 portions of the program Part B of KOURAGE 1 and the second study KOURAGE 2.
• The company expects to release final topline results from the first pivotal study KOURAGE 1 Part B by the end of 2025 with the second pivotal study KOURAGE 2 results in early 2026.

Key Dates

Keywords

difelikefalin, pruritus, notalgia paresthetica, KORSUVA, Kapruvia, clinical trial, biopharmaceutical, revenue, operating expenses, HCR, royalty, Phase 2/3, CKD, hemodialysis